Log in

Relevant bibliographies by topics / Pharmaceutical policy

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Pharmaceutical policy'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pharmaceutical policy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Pharmaceutical policy"

1

Alajärvi, Lasse, Johanna Timonen, Piia Lavikainen, and Janne Martikainen. "Attitudes and Considerations towards Pharmaceuticals-Related Environmental Issues among Finnish Population." Sustainability 13, no. 22 (2021): 12930. http://dx.doi.org/10.3390/su132212930.

Full text

Abstract:

A number of policy recommendations identify the general public as a key participant in environmentally sustainable pharmaceutical policies. However, research into pharmaceuticals-related environmental issues from the population perspective is scarce. We studied the awareness among Finnish adults (n = 2030) of pharmaceutical residues in Finnish waterways, their perceived environmental sources, views on pharmaceuticals-related environmental issues, and their association with background characteristics. Of the respondents, 89.5% were aware of the presence of pharmaceuticals in Finnish waterways.

APA, Harvard, Vancouver, ISO, and other styles

2

Iyengar, Renganthan. "PHARMACEUTICAL PRICING POLICY AND CONTROL– INDIAN PERSPECTIVE." Asian Journal of Pharmaceutical and Clinical Research 9, no. 6 (2016): 305. http://dx.doi.org/10.22159/ajpcr.2016.v9i6.14461.

Full text

Abstract:

ABSTRACTPharmaceutical sector is playing a vital role towards the wellness of the people and economic development of India. The innovation, development, production and marketing of medicines are accountable to pharmaceutical industry. Drugs and pharmaceuticals, healthcare delivery, medical devices among others come under the purview of healthcare sector. It is the duty of the Government to ensure the availability of the lifesaving drugs at reasonable prices by means of considering the interest of both the producers and the buyers. In order to safeguard the public health, National Pharmaceutica

APA, Harvard, Vancouver, ISO, and other styles

3

Probyn, Andrew J. "Some drugs more equal than others: pseudo-generics and commercial practice." Australian Health Review 28, no. 2 (2004): 207. http://dx.doi.org/10.1071/ah040207.

Full text

Abstract:

This article analyses the impact of the Department of Health and Ageing?s brand price premium policy for some products listed on the Pharmaceutical Benefits Scheme. The policy, introduced in 1990, allows pharmaceutical companies to charge patients an out-of-pocket expense for post-patent brands of pharmaceuticals. One of the policy?s intended goals was to increase consumer awareness of price differentials between competing brands, with a view to encouraging greater use of cheaper generic products. More than fourteen years since its introduction, it is debatable whether the policy has achieved

APA, Harvard, Vancouver, ISO, and other styles

4

Weiss, Lawrence D., and Stuart O. Schweitzer. "Pharmaceutical Economics and Policy." Journal of Public Health Policy 19, no. 3 (1998): 379. http://dx.doi.org/10.2307/3343547.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Mullins, C. Daniel. "Pharmaceutical prices and policy." Clinical Therapeutics 26, no. 8 (2004): 1326. http://dx.doi.org/10.1016/s0149-2918(04)80193-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Sun, Qiang, Michael A. Santoro, Qingyue Meng, Caitlin Liu, and Karen Eggleston. "Pharmaceutical Policy In China." Health Affairs 27, no. 4 (2008): 1042–50. http://dx.doi.org/10.1377/hlthaff.27.4.1042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Garattini, Livio, and Dante Cornago. "Pharmaceutical policy in Italy." European Journal of Health Economics 7, no. 2 (2006): 89–90. http://dx.doi.org/10.1007/s10198-006-0353-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

CONTRACTOR, SUNIL H., PIYUSH KUMAR, and THOMAS W. LEIGH. "THE IMPACT OF GOVERNANCE MECHANISMS ON ESCALATION OF COMMITMENT." International Journal of Innovation Management 16, no. 04 (2012): 1250023. http://dx.doi.org/10.1142/s1363919612500235.

Full text

Abstract:

There are conflicting opinions on whether the existing US legal and economic environment for pharmaceutical research is conducive for the repurposing of patent-protected drugs. This article therefore addresses the following innovation policy questions: Does US patent law and regulatory policy assign sufficient value to new use patents in the pharmaceutical industry? If present law and regulatory policy does assign sufficient value, what evidence is there that the pharmaceutical industry is actively involved in technology strategies to repurpose existing pharmaceuticals? Based on an evaluation

APA, Harvard, Vancouver, ISO, and other styles

9

ROEMER-MAHLER, ANNE. "The rise of companies from emerging markets in global health governance: Opportunities and challenges." Review of International Studies 40, no. 5 (2014): 897–918. http://dx.doi.org/10.1017/s0260210514000345.

Full text

Abstract:

AbstractThe article analyses the involvement of pharmaceutical companies from emerging markets in global health governance. It finds that they play a central role as low-cost suppliers of medicines and vaccines and, increasingly, new technologies. In so doing, pharmaceutical companies from emerging markets have facilitated the implementation of a key goal of global health policy: widening access to pharmaceutical treatment and prevention. Yet, looking closer at the political economy underlying their involvement, the article exposes a tension between this policy goal and the political economy o

APA, Harvard, Vancouver, ISO, and other styles

10

Gautam, Tara Prashad. "HRM Practices and its Impact on Customers’ Satisfaction of Pharmaceutical Companies in Nepal." Nepal Journal of Multidisciplinary Research 4, no. 4 (2021): 63–69. http://dx.doi.org/10.3126/njmr.v4i4.43210.

Full text

Abstract:

This paper aims to investigate the HRM practices and impact on Customers satisfaction in the pharmaceutical companies of Nepal A structured questionnaire was developed and distributed among 386 employees of 37 pharmaceuticals companies. Statistical correlation analysis was used to assess the impact of HRM practices on Customer satisfaction. The study reveals that employees in pharmaceutical companies are satisfied with the recruitment and selection, and training and development policy and practices of pharmaceutical companies. On the other hand, employees are dissatisfied with the human resour

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Pharmaceutical policy"

1

Lee, Iynhyang. "Evaluating pharmaceutical policy in South Korea." Thesis, University of York, 2010. http://etheses.whiterose.ac.uk/14150/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Kiatying-Angsulee, Niyada. "Pharmaceutical registration policy in Thailand : development and implementation." Thesis, London School of Hygiene and Tropical Medicine (University of London), 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.392683.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Permanand, Govin. "Regulating under constraint : the case of EU pharmaceutical policy." Thesis, London School of Economics and Political Science (University of London), 2003. http://etheses.lse.ac.uk/1940/.

Full text

Abstract:

This study is concerned with the making of regulatory policy for pharmaceuticals in the European Union. It proposes that an ad hoc development of Community competencies which does not amount to coherent strategy, far less a single medicines market, has resulted in a regulatory framework which favours the interests of industry. This is important on two fronts. First, it appears to run counter to contemporary research into EU regulation, which finds that consumer interests prevail over those of producers generally. Second, this pro-industry leaning seems not to be in keeping with member states'

APA, Harvard, Vancouver, ISO, and other styles

4

Ozierański, Piotr. "Who rules postcommunism? : the case of drug reimbursement policy in Poland." Thesis, University of Cambridge, 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.610488.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Granlund, David. "Economic policy in health care : Sickness absence and pharmaceutical costs." Doctoral thesis, Umeå : Department of Economics, Umeå University, 2007. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1137.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Hayashi, Yuko. "Japanese government policy to innovative R&D in pharmaceutical industry." Thesis, Massachusetts Institute of Technology, 1994. http://hdl.handle.net/1721.1/35990.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Sales, Raquel da Silva. "National Drug Policy, Decentralization, Pharmaceutical Assistance, Essential Medicines, Access to medicines." Universidade Federal do CearÃ, 2008. http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=2937.

Full text

Abstract:

nÃo hÃ<br>This dissertation aims to investigate the influence of drugs decentralization policy on the free access to medicine in the Northeast region, which started after the publication of the National Drug Policy (NDP). As a result, using the microdata special supplement of Health from PNAD 1998 (year before the issue of the NDP) and 2003 (five years after the NDP), it was estimated nine functional forms of logit model with fixed effect for the nine states of Northeast Brazil. The results implies that, after the policy, the probability to free medicines access was improved for almost all sta

APA, Harvard, Vancouver, ISO, and other styles

8

Corvari, Ronald J. (Ronald Joseph) Carleton University Dissertation Economics. "Strategic advertising behaviour and public policy in the Canadian pharmaceutical industry." Ottawa, 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Kundu, Jayeeta. "Cross-country study on the promotion of new pharmaceutical products." Thesis, Massachusetts Institute of Technology, 2006. http://hdl.handle.net/1721.1/34524.

Full text

Abstract:

Thesis (S.M.)--Massachusetts Institute of Technology, Engineering Systems Division, Technology and Policy Program, 2006.<br>Includes bibliographical references (p. 170-176).<br>Detailers are one of the most powerful components of pharmaceutical marketing. Drug manufactures spend a lion's share of their marketing budgets on their detailers, and with direct-to-consumer (DTC) marketing coming under closer scrutiny, it is likely that detailing will receive even more funding in the coming years. This thesis analyzes how differences in detailing regulations in the United States, United Kingdom, Swed

APA, Harvard, Vancouver, ISO, and other styles

10

Boothe, Katherine. "Pharmaceutical programs and social policy development: comparing Canada, Australia and the UK." Thesis, University of British Columbia, 2010. http://hdl.handle.net/2429/26266.

Full text

Abstract:

Canada is the only OECD country that provides broad public health benefits but lacks a universal, nation-wide system for funding prescription drugs. This puzzle cannot be explained by the literature on national health insurance, which suggests that the tendency to consider all health services as a single policy has missed an important source of cross-national variation. How can we explain the lack of a major pharmaceutical program in Canada, in light of the country’s own extensive health system and the experience of almost all other welfare states? More generally, why do some countries adopt u

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Pharmaceutical policy"

1

Babar, Zaheer-Ud-Din, ed. Global Pharmaceutical Policy. Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-15-2724-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Swaziland. National pharmaceutical policy. 2nd ed. Kingdom of Swaziland, Ministry of Health, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

McKoy, June M., and Dennis P. West, eds. Cancer Policy: Pharmaceutical Safety. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-43896-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Schweitzer, Stuart O. Pharmaceutical economics and policy. Oxford University Press, 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Jain, S. K. The drug policy, 1987-88: Supplement. India Investment Publication, 1987.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Massard da Fonseca, Elize. The Politics of Pharmaceutical Policy Reform. Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-12565-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Bank, World, ed. A practical approach to pharmaceutical policy. World Bank, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Health, Malawi Ministry of. Malawi national drug policy. The Ministry, 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Wiggins, Steven N. The pharmaceutical industry. Center for Education and Research in Free Enterprise, Texas A&M University, 1985.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Saúde, Timor-Leste Ministério da. National drugs and medicine policy. Ministry of Health, Republic of Timor Leste, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Pharmaceutical policy"

1

Mendoza-Ruiz, Adriana, Angela Acosta, Egdda Patricia Vanegas Escamilla, and María Cristina Latorre Torres. "Pharmaceutical Policy in Colombia." In Pharmaceutical Policy in Countries with Developing Healthcare Systems. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-51673-8_10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Durán, Carlos E., Ruth Lucio, and Joan Rovira. "Pharmaceutical Policy in Ecuador." In Pharmaceutical Policy in Countries with Developing Healthcare Systems. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-51673-8_11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

El-Dahiyat, Faris, and Louise Elizabeth Curley. "Pharmaceutical Policy in Jordan." In Pharmaceutical Policy in Countries with Developing Healthcare Systems. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-51673-8_12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Khabriev, Ramil, Dmitry Meshkov, Liudmila Bezmelnitsyna, Sergey Cherkasov, Evgenya Berseneva, and Shane Scahill. "Pharmaceutical Policy in Russia." In Pharmaceutical Policy in Countries with Developing Healthcare Systems. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-51673-8_13.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Wlodarczyk, Irmina, and Shane L. Scahill. "Pharmaceutical Policy in Poland." In Pharmaceutical Policy in Countries with Developing Healthcare Systems. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-51673-8_15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Atif, Muhammad, Mahmood Ahmad, Quratulain Saleem, Louise Curley, Muhammad Qamar-uz-Zaman, and Zaheer-Ud-Din Babar. "Pharmaceutical Policy in Pakistan." In Pharmaceutical Policy in Countries with Developing Healthcare Systems. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-51673-8_3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Nguyen, Tuan Anh, Agnes Vitry, and Elizabeth E. Roughead. "Pharmaceutical Policy in Vietnam." In Pharmaceutical Policy in Countries with Developing Healthcare Systems. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-51673-8_5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Vargas-Pelaez, Claudia Marcela, María Teresa Bürgin Drago, Angela Acosta, and Mareni Rocha Farias. "Pharmaceutical Policy in Argentina." In Pharmaceutical Policy in Countries with Developing Healthcare Systems. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-51673-8_6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Luiza, Vera Lucia, Maria Auxiliadora Oliveira, Gabriela Costa Chaves, Matthew B. Flynn, and Jorge Antonio Zepeda Bermudez. "Pharmaceutical Policy in Brazil." In Pharmaceutical Policy in Countries with Developing Healthcare Systems. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-51673-8_7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Lopert, Ruth. "Pharmaceutical Policy in Bulgaria." In Pharmaceutical Policy in Countries with Developing Healthcare Systems. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-51673-8_8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Pharmaceutical policy"

1

Stone, A., and K. Flamm. "Knowledge and productivity in the pharmaceutical industry." In 2009 Atlanta Conference on Science and Innovation Policy. IEEE, 2009. http://dx.doi.org/10.1109/acsip.2009.5367866.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Putranti, Titi, and Amri, Rafli. "Implementation of Value Added Tax Policy on Pharmaceutical in Indonesia." In Proceedings of the 3rd International Conference on Administrative Science, Policy, and Governance Studies, ICAS-PGS 2019, October 30-31, Universitas Indonesia, Depok. Indonesia. EAI, 2020. http://dx.doi.org/10.4108/eai.30-10-2019.2299412.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Putilkina, Alyona Yurievna, Alexander Ivanovich Utkin, Albina Valentinovna Utkina, Ella Viktorovna Romanova, and Elena Viktorovna Gromova. "THE CURRENT STATE OF THE PHARMACEUTICAL INDUSTRY IN THE RUSSIAN FEDERATION." In Themed collection of papers from Foreign international scientific conference «Joint innovation - joint development». Part 2. by HNRI «National development» in cooperation with PS of UA. October 2023. - Harbin (China). Crossref, 2024. http://dx.doi.org/10.37539/231024.2023.36.49.060.

Full text

Abstract:

This article provides an overview and analysis of the current situation in the pharmaceutical industry in Russia. It examines the key trends, challenges, and opportunities faced by companies operating in this sector. The article presents data on the overall dynamics of the Russian pharmaceutical industry, including the origin structure of medicinal products. It showcases the general volumes of pharmaceutical production in terms of quantity and value for the year 2023. It also highlights the priority directions of state policy and trends in the development of the industry in the country. Additi

APA, Harvard, Vancouver, ISO, and other styles

4

Bansal, Ajit, Anurag Tewari, Gaurav Katoch, Ankur Budhiraja, and Anu Bansal. "Challenges and policy approach to transfer of technology in the pharmaceutical sector." In RECENT ADVANCES IN SCIENCES, ENGINEERING, INFORMATION TECHNOLOGY & MANAGEMENT. AIP Publishing, 2023. http://dx.doi.org/10.1063/5.0155590.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Chen, Xin, Xingzheng Ai, and Li Zhong. "The Impact of Medical Services and Medicine Separation Policy on Competitive Pharmaceutical Supply Chain Performance." In 2018 15th International Conference on Service Systems and Service Management (ICSSSM). IEEE, 2018. http://dx.doi.org/10.1109/icsssm.2018.8464964.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Chernysheva, Yu A. "State Criminal Policy in the Field of Preventing Offences Committed on the Pharmaceutical Market Objects." In XVII International Research-to-Practice Conference dedicated to the memory of M.I. Kovalyov (ICK 2020). Atlantis Press, 2020. http://dx.doi.org/10.2991/assehr.k.200321.084.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Ibrahim, Meram, Banan Mukhalalati, Majdoleen Al alawneh, and Ahmed Awaisu. "Qatar National Vision 2030." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0226.

Full text

Abstract:

Introduction: The United Nations launched the Sustainable Development Goals in 2015. One of these goals describes achieving a Universal Health Coverage by 2030. This signifies workforce planning in healthcare professions (United Nations, 2015). The International Pharmaceutical Federation (FIP) published reports about pharmacy workforce planning in several countries. However, data about Qatar was not included in these reports. In 2017, FIP developed a transformational roadmap of pharmaceutical workforce and education. One component of the roadmap is the Pharmaceutical Workforce Development Goal

APA, Harvard, Vancouver, ISO, and other styles

8

"Two Decades Post the Agreement on Trade Related Aspects of Intellectual property Rights (TRIPS): Analytical perspectives on cases of pharmaceutical patent disputes." In 2nd Annual International Conference on Law, Regulations and Public Policy (LRPP 2013). Global Science and Technology Forum Pte Ltd, 2013. http://dx.doi.org/10.5176/2251-3809_lrpp13.43.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Roisah, Kholis, Rahayu Rahayu, Darminto Darminto, and Leony Suryani. "Local Working Requirement on Patens Policy for Pharmaceutical Products and Its Relation to Right in Public Health." In Proceedings of the 2nd International Conference on Law, Economic, Governance, ICOLEG 2021, 29-30 June 2021, Semarang, Indonesia. EAI, 2021. http://dx.doi.org/10.4108/eai.29-6-2021.2312624.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Arini, Wahyu Eka, and Dumilah Ayuningtyas. "The Implementation of Pharmaceutical Service Standard Policy for Accreditation of the Community Health Center in Bekasi, West Java." In The 5th International Conference on Public Health 2019. Masters Program in Public Health, Universitas Sebelas Maret, 2019. http://dx.doi.org/10.26911/theicph.2019.04.55.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Pharmaceutical policy"

1

Kibira, Denis, Geofrey Opio Atim, Richard Hasunira, and Aziz Maija. Assessment of the Legal, Policy and Operational Environment of Pharmaceutical Manufacturers Associations in Africa. Afya na Haki, 2023. http://dx.doi.org/10.63010/wn8d.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Saha, Amrita, Juan Manuel Del Pozo Segura, and Gabriel Palazzo. Firm-Level Innovation and the Role of Political Capabilities: Evidence for the Pharmaceuticals Industry. Institute of Development Studies, 2025. https://doi.org/10.19088/ids.2025.036.

Full text

Abstract:

The global debate on balancing incentives for innovation in the pharmaceutical industry and facilitating competition for greater access to affordable medicines and vaccines has intensified in the aftermath of the Covid-19 pandemic. Drug discovery and vaccine development are expensive processes involving significant research and development (R&D) costs. And while the economic fundamentals of incentivising innovation for the pharmaceutical industry are traditionally linked to patenting, several scholars have highlighted the inefficiencies and greater appropriation of the returns from R&D

APA, Harvard, Vancouver, ISO, and other styles

3

McCoy, David, and Penelope Milsom. Corporate accountability: A case study of the Access to Medicine Index Does it help or hinder global health? United Nations University - International Institute for Global Health, 2025. https://doi.org/10.37941/pb/2025/1.

Full text

Abstract:

The Access to Medicine Index (AtMI) is an instrument that ranks the 20 biggest pharmaceutical TNCs according to how well they perform in terms of improving access to medicines and other pharmaceutical products in low- and middle-income countries (L&MICs). It is viewed as an instrument that incentivises companies and their investors to adopt more socially responsible policies and practices that would benefit populations in poorer countries. As part of its work on corporate power and accountability, UNU-IIGH conducted a detailed study of the 2022 and 2024 AtMI. This policy brief presents a s

APA, Harvard, Vancouver, ISO, and other styles

4

Gutiérrez, Catalina, and Úrsula Giedion. How Many Healthy Life years could Countries in Latin America and the Caribbean Gain with a Better Allocation of Pharmaceutical Spending?: Case Studies for Chile, Colombia, and the Dominican Republic. Inter-American Development Bank, 2023. https://doi.org/10.18235/0005161.

Full text

Abstract:

Health spending is increasing globally due to demographic and epidemiological changes, rising demand for services driven by higher incomes, aging populations, and the emergence of expensive new health technologies. In Latin America and the Caribbean (LAC), health expenditure has risen from 6.6% to 7.9% of GDP over the past two decades. By 2030, it is expected to increase by another 2 percentage points. This projection excludes additional investments required to strengthen health systems post-pandemic. Given fiscal constraints caused by the pandemics economic impact, rising debt, and macroecono

APA, Harvard, Vancouver, ISO, and other styles

5

Ssekamwa, Frank, Moses Mulumba, Baguma Christopher, et al. STAKEHOLDER MAPPING & ANALYSIS REPORT Key Players with Legal and Policy mandates to implement and regulate a Sustainable Pharmaceutical Manufacturing Ecosystem for Africa. Afya na Haki, 2023. http://dx.doi.org/10.63010/w5ioy43.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Fry, Emily, James Smith, and Gregory Thwaites. Trump tariff turmoil: The impact of higher US tariffs and the risk of a global recession. The Resolution Foundation, 2025. https://doi.org/10.63492/urwi832.

Full text

Abstract:

President Trump’s tariff announcements have taken a wrecking ball to the global system of international trade, pushing US tariff rates back to early 20th century levels. Following the suspension of ‘reciprocal’ tariffs, the UK’s exposure to automotive and possible “major” pharmaceutical tariffs, means we are set to be affected by more than many other countries, with the notable exception of China. But as well as the direct impacts of the tariffs, President Trump’s approach to policy making has led to huge uncertainty about the ‘new normal’ for tariffs. This uncertainty has triggered wild swing

APA, Harvard, Vancouver, ISO, and other styles

7

Ssebibubbu, Stuart, Moses Mulumba, Monalisa Chafewa, Maria Birungi, Nimrod Muhumuza, and Baguma Christopher. Analyzing the Capacities of National Medicines Regulatory Agencies To Regulate Vaccine Manufacturing in Africa. Afya na Haki, 2023. http://dx.doi.org/10.63010/k8nm.

Full text

Abstract:

Pharmaceutical production and high-quality medical treatment require effective regulation. National Medicines Regulatory Authorities (NMRAs) oversee medicinal product manufacture, distribution, and sale. Analysing African NMRA capacity is necessary to identify gaps and improve regulatory mechanisms to ensure vaccination quality and public health. This paper employs qualitative methodology to analyze the legal, regulatory, and policy framework systems, which includes a desk review of relevant literature, a writing workshop, and key informant interviews as data sources in Eight countries, includ

APA, Harvard, Vancouver, ISO, and other styles

8

Chan, Leong. Developing a Strategic Policy Choice Framework for Technological Innovation: Case of Chinese Pharmaceuticals. Portland State University Library, 2000. http://dx.doi.org/10.15760/etd.1041.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Ruiz de Gauna, Itziar, Anil Markandya, Laura Onofri, et al. Economic Valuation of the Ecosystem Services of the Mesoamerican Reef, and the Allocation and Distribution of these Values. Inter-American Development Bank, 2021. http://dx.doi.org/10.18235/0003289.

Full text

Abstract:

Coral reefs are one of the most diverse and valuable ecosystems on Earth. The Mesoamerican Reef contains the largest barrier reef in the Western Hemisphere. However, its health is threatened, so there is a need for a management and sustainable conservation. Key to this is knowing the economic value of the ecosystem. “Mainstreaming the value of natural capital into policy decision-making is vital” The value of environmental and natural resources reflects what society is willing to pay for a good or service or to conserve natural resources. Conventional economic approaches tended to view value o

APA, Harvard, Vancouver, ISO, and other styles

10

McQuinn, Kieran, Conor O'Toole, and Dónal O'Shea. Quarterly Economic Commentary, Spring 2025. ESRI, 2024. https://doi.org/10.26504/qec2025spr.

Full text

Abstract:

At the start of 2025, the Irish economy is in a strong position. Unemployment stands at 3.9 per cent, while real income growth is set to exceed 3.5 per cent in the current year. Exchequer returns continue to increase quite significantly for the opening period of the present year. Therefore, as a baseline, we expect modified domestic demand (MDD) to increase by 3.0 per cent in 2025 and 2.8 per cent in 2026. These forecasts are conducted on the assumption of no trade tariffs being imposed between the United States (US) and the European Union (EU). However, the international climate is particular

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!